The review of the foreign experience on the financing of innovative medical technologies
Abstract
The article presents a review of the foreign approaches to the mechanisms of financing of medical help and innovative medical technologies with the description of the implemented financial mechanisms of stimulation of innovations in foreign systems of public healthcare. Since the system of payment for diagnosis-related groups (DRG) does not contribute to the implementation of innovations in the medical practice, the majority of countries apply additional mechanisms of financing of innovative technologies in public healthcare such as single and additional payments, and target financing that was initially not associated with a DRG model.
About the Authors
V. V. OmelyanovskiyRussian Federation
Vitaly V. Omelyanovskiy – MD, Dr Sci Med, Professor, General Director; Head of the Center for Healthcare Funding; Head of the Chair of Healthcare Economics, Management and Technology Assessment, Russian Medical Academy of Continuous Professional Education, Researcher ID:
P-6911-2018, Scopus Author ID: 6507287753, 10-5 Khokhlovskii pereulok, Moscow 109028, Russia; 3-2 Nastasyinsky pereulok, Moscow 127006, Russia
I. A. Zheleznyakova
Russian Federation
Inna A. Zheleznyakova – Deputy Director-General, 10-5 Khokhlovskii pereulok, Moscow 109028, Russia
T. P. Bezdenezhnykh
Russian Federation
Tatiana P. Bezdenezhnykh – Lead Specialist; Junior Researcher at the Center for Healthcare Funding, 10-5 Khokhlovskii pereulok, Moscow 109028, Russia; 3-2 Nastasyinsky pereulok, Moscow 127006, Russia
M. L. Lazareva
Russian Federation
Mariya L. Lazareva – Deputy Chief, Department for Methodological Support of Payment for Medical Care, 10-5 Khokhlovskii pereulok, Moscow 109028, Russia
D. V. Fedyaev
Russian Federation
Denis V. Fedyaev – Head of the department for collection, processing, and analysis of indicators of financial support for health care; Research Fellow at the Laboratory for HTA at the Institute of Applied Economic Research of the Russian Academy of Science, 10-5 Khokhlovskii pereulok, Moscow 109028, Russia; 3-2 Nastasyinsky pereulok, Moscow 127006, Russia; 82 Vernadskogo prospect, Moscow 119571, Russia
References
1. Moullin J.C. et al. A systematic review of implementation frameworks of innovations in healthcare and resulting generic implementation framework. Health Research Policy and Systems. 2015; 13 (1): 1–11.
2. OTA-TM-H-17. Diagnosis Related Groups (DRGs) and the Medicare Program: Implications for Medical Technology. Washington. 1983.
3. Cutler D.M., McClellan M. Is technological change in medicine worth it? Health Affairs. 2001; 20 (5): 11–29.
4. Scheller-Kreinsen D., Quentin W., Busse R. DRG-based hospital payment systems and technological innovation in 12 European countries. Value in Health. 2011; 14 (8): 1166–1172.
5. Stephani V., Quentin W., Van den Heede K., Van de Voorde G.A. Payment methods for hospital stays with a large variability in the care process. Belgian Health Care Knowledge Centre (KCE). 2018.
6. Busse R. et al. Diagnosis related groups in Europe: Moving towards transparency, efficiency, and quality in hospitals? BMJ (Online). 2013; 347 (7916).
7. Milcent C. French DRG-Based Payment: First Feedback on Cost Variability. Economie prevision. 2017; 210 (1): 45–67.
8. Ex P. et al. The reimbursement of new medical technologies in German inpatient care: What factors explain which hospitals receive innovation payments? Health Economics. 2019; 15 (3): 355–369.
9. NUB Application – How is this created and what should I consider? [Electronic resource]. URL: https://reimbursement.institute/en/nub-application/. Accessed: 30.06.2020.
10. Henschke C. et al. Extrabudgetary (‘NUB’) payments: A gateway for introducing new medical devices into the German inpatient reimbursement system? Journal of Management & Marketing in Healthcare. 2010; 3 (2): 119–133.
Review
For citations:
Omelyanovskiy V.V., Zheleznyakova I.A., Bezdenezhnykh T.P., Lazareva M.L., Fedyaev D.V. The review of the foreign experience on the financing of innovative medical technologies. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(3):316-323. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.055

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.